Human RNase H and compositions and uses thereof
OwnerStanley T. Crooke, Walter Lima +1inventors
InventorsStanley T. Crooke, Walter Lima, Hongjiang Wu
Life of this patent
Estimating the term…
Abstract
The present invention provides polynucleotides and polypeptides encoded thereby of human Type 2 RNase H. Methods of using these polynucleotides and polypeptides in enhancing antisense oligonucleotide therapies are also provided.
Claims12
An isolated polynucleotide encoding the human Type 2 RNase H polypeptide (SEQ ID NO:
- 6):
A vector comprising a nucleic acid encoding the human Type 2 RNase H (SEQ ID NO:
- 6).
A composition comprising a vector comprising a nucleic acid encoding the human Type 2 RNase H polypeptide (SEQ ID NO:
- 6).
A composition comprising an antisense oligonucleotide and a human Type 2 RNase H polypeptide, wherein the human Type 2 RNase H polypeptide is the human Type 2 RNase H polypeptide (SEQ ID NO:
- 6).
A human Type 2 RNase H--his-tag fusion polypeptide, wherein the human Type 2 RNase H polypeptide is the human Type 2 RNase H polypeptide (SEQ ID NO:
- 6).
A method of identifying an effective antisense oligonucleotide for inhibition of expression of a selected target protein comprising:
- (a) contacting the human Type 2 RNase H polypeptide (SEQ ID NO:
- 6) with an RNA encoding the selected target protein and an oligonucleotide complementary to at least a portion of the RNA under conditions in which an RNA-oligonucleotide duplex is formed;
- (b) detecting one or more RNA cleavage products wherein cleavage products of the RNA of the RNA-oligonucleotide duplex are indicative of antisense efficacy.
A method of identifying agents which increase or decrease activity or levels of the human Type 2 RNase H polypeptide (SEQ ID NO:
- 6) in a host cell comprising:
- (a) contacting a cell in vitro expressing the human Type 2 RNase H polypeptide with an agent suspected of increasing or decreasing activity or levels of the human Type 2 RNase H polypeptide;
- and
- (b) measuring the activity or levels of the human Type 2 RNase H polypeptide in the presence and absence of the agent so that an increase or decrease in the activity or levels of the human Type 2 RNase H polypeptide can be determined.
Dependencies are inferred from the claim text.